Treatment of adult recurrent multiple sclerosis Novartis Class 1 new drug Sinimod on the market in China

Medical Network May 13 hearing May 11, the State Food and Drug Administration announced approval of a Class 1 drug innovation Fuad Maude sheet (trade name: Wan Li can) NovartisPharmaAG declared priority review by the listing approval process for treatment of adults with relapsing forms of multiple sclerosisMeters within the network data show that the product in 2019 global sales of $ 26 millionFIG1:Source review Sydney Maude: 2.0m MED network database reported that Chinese Drug Evaluation, Sydney is a Maude kinds of sphingosine-1-phosphate (S1P) receptor modulator, a selective and S1P receptor subtype 1 (S1P1) and subtype 5 (S1P5) binding with high affinity, to prevent escape of lymphocytes from lymph nodes, peripheral blood to reduce the number of lymphocytesNovartisPharmaAG declared class innovative drugs 1 Sidney Maude sheet (trade name: Wan Li can) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing - remittingand advancement of secondary activity type of disease, the species listed as relapsing forms of multiple sclerosis patients with a new treatment option to better meet the clinical needs of patientssome dual mechanism, on the one hand to prevent of lymphocytes into the central nervous system of MS patients, anti-inflammatory effect functions; on the other hand can play directly promote remyelination in the central nervous system provided neuroprotective effectSydney Maude in March 2019 approved in the United States, in January 2020, approved in the EUSource: NMPA official website, databasereview of meters within the network statistics as of 2020 May 9, if imperfect, please correct me!